{"id":"W2914258217","doi":"10.1002/cncr.31999","title":"Hyperprogressive disease in early‐phase immunotherapy trials: Clinical predictors and association with immune‐related toxicities","year":2019,"lang":"en","type":"article","venue":"Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Genentech; Servier; Astellas Pharma; MacroGenics; Agios Pharmaceuticals; Regeneron Pharmaceuticals; EMD Serono; Mersana Therapeutics; Karyopharm Therapeutics; PTC Therapeutics; Sanofi; GlaxoSmithKline; Amgen; Pfizer; MorphoSys; Celgene; Symphogen; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Discontinuation; Immunotherapy; Internal medicine; Clinical trial; Oncology; Response Evaluation Criteria in Solid Tumors; Cancer; Disease; Adverse effect; Phases of clinical research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011415,0.0001692414,0.000647273,0.00009441716,0.00003608344,0.00003117901,0.0000589586,0.0001608951,0.0005434185],"category_scores_gemma":[0.0001127811,0.0001194662,0.0001581328,0.0002063814,0.0001106118,0.0001278562,0.000009826778,0.0002629424,0.000008993889],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002978912,"about_ca_system_score_gemma":0.0002980355,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002111448,"about_ca_topic_score_gemma":0.00001793227,"domain_scores_codex":[0.9983091,0.0002157294,0.0006813238,0.000288419,0.0002680728,0.0002373864],"domain_scores_gemma":[0.9989319,0.0002836941,0.0003739293,0.0002295338,0.00007608841,0.0001047816],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01906957,0.0002187676,0.9443377,0.00004615654,0.0006524574,0.00001515199,0.0009123826,0.000003255717,0.003427943,0.000010174,0.0001768762,0.03112962],"study_design_scores_gemma":[0.03014352,0.001212125,0.9604394,0.0006910767,0.0001808344,0.000002925718,0.0001546284,0.0001020527,0.0007765524,0.00003085197,0.006058619,0.0002074018],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9722897,0.02501746,0.000003632269,0.0008679351,0.0005600443,0.0009889049,0.00004869534,0.00004481397,0.0001788284],"genre_scores_gemma":[0.9887493,0.008536053,0.00001953917,0.0003991506,0.0001337684,0.0001266727,0.00002352332,0.00003055126,0.001981451],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03092222,"threshold_uncertainty_score":0.5950051,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02489880989038091,"score_gpt":0.3612984301281122,"score_spread":0.3363996202377313,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}